FGFR2

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

Retrieved on: 
Thursday, August 18, 2022
U.S. Securities and Exchange Commission, ESMO, Compte rendu, Risk, Drug discovery, GLOBE, 2021 Essex County Council election, Preclinical development, Private Securities Litigation Reform Act, Clinical trial, Congress, Security (finance), Annual report, Cancer, Patient, European Society for Medical Oncology, Therapy, COVID-19, Family, Twitter, CCA, Publication, News, FGFR, Safety, FGFR2, Webcast, Protein, Nasdaq, Pharmaceutical industry

Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T.

Key Points: 
  • Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T.
  • The ESMO website indicates that late breaking abstracts will be published on the September 7, 2022 at 7:05 pm E.T.
  • Relay Therapeutics will host a conference call and live webcast on September 12, 2022 at 8:00 am E.T.
  • The presentation from the ESMO Congress will also be available on the Relay Therapeutics website under Publications: https://relaytx.com/publications/ .

LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, City, Demodex, NDA, Forward-looking statement, GLOBE, Population, Growth, SEC, Clinical trial, Cisplatin, Inflammation, Pfizer, Respiratory syncytial virus, Department, NBTXR3, Marketing, Patient, COVID-19, Company, Large-cell lung carcinoma, Acquisition, CCA, Biotechnology, Safety, FGFR, FGFR2, Â, Research, Oxford Handbook of Clinical Medicine, Ulcerative colitis, Department of Health and Social Care, Ophthalmology, Food, Pharmaceutical industry, Medicine

In August 2022, enrollment was completed in the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with oHCM.

Key Points: 
  • In August 2022, enrollment was completed in the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with oHCM.
  • In August 2022, Landos announced topline results from a Phase 1b clinical trial of NX-13 demonstrating NX-13 was well tolerated.
  • LianBio expects to initiate a Phase 3 study in Chinese patients with Demodex blepharitis in the second half of 2022.
  • LianBio expects to initiate a Phase 1 monotherapy clinical trial of BBP-398 in advanced solid tumors in the fourth quarter of 2022.

Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, American Society of Human Genetics, CDK2, CEO, GLOBE, Investment, Clinical trial, Security (finance), Research, Annual report, Massachusetts General Hospital, Patient, Cardiovascular disease, CCA, FGFR2, Food, Risk, Internal medicine, Private Securities Litigation Reform Act, Myocardial infarction, History, Breast cancer, Safety, SHP2, HR, Nasdaq, Broad Institute, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Interim, Hospital, Drug discovery, University, QD, Gene editing, Framingham Heart Study, Therapy, COVID-19, D, Acquisition, Harvard Medical School, American Heart Association, Genetic distance, FDA, Fulvestrant, Compte rendu, Verve, Cardiology, Society, Human genetics, Genetics, MGH, Center, Twitter, Medicine, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) --  Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported second quarter 2022 financial results and recent corporate highlights.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported second quarter 2022 financial results and recent corporate highlights.
  • R&D Expenses: Research and development expenses were $60.5 million for the second quarter of 2022, as compared to $45.1 million for the second quarter of 2021.
  • G&A Expenses: General and administrative expenses were $17.5 million for second quarter of 2022, as compared to $14.4 million for the second quarter of 2021.
  • Relay Therapeutics initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Market Insights 2022: Coverage of 15 Companies and Respective Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, Health, Clinical Trials, Antagonist, Patient, Fibroblast growth factor receptor 4, HCC, Pemigatinib, II, FGFR4, Receptor tyrosine kinase, Therapy, FGFR2, Clinical trial, Discovery, Hepatocellular carcinoma, BTC, FGFR, News, Fine chemical, Pharmaceutical industry

This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.

Key Points: 
  • This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment
    This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

Retrieved on: 
Monday, June 27, 2022
FDA, Annual report, CDK, Patient, Protein, Breast cancer, Preclinical development, Therapy, GLOBE, COVID-19, Program, Company, U.S. Securities and Exchange Commission, Interim, CCA, CDK2, Hyperphosphatemia, Toxicity, Compte rendu, Risk, Food, Cancer, FGFR2, Investment, BID, Security (finance), Clinical trial, Private Securities Litigation Reform Act, Drug discovery, Nasdaq, FGFR, News, Diarrhea, Family, Webcast, Safety, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mutation, NDA, QD, Pharmaceutical industry

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will announce today the anticipated registrational path for RLY-4008 and three new programs within a growing HR+/HER2- breast cancer franchise at a virtual analyst and investor event from 8:00 a.m. to 9:00 a.m. ET.

Key Points: 
  • We are excited to be announcing the anticipated registrational path for RLY-4008 and the maturation of the data to support that pathway.
  • In addition, building on the foundation of our PI3K franchise, we will outline a broad commitment to developing comprehensive treatment options for breast cancer patients.
  • Relay Therapeutics conducted an end-of-phase 1 meeting with the FDA to discuss next steps for the clinical development of RLY-4008.
  • The virtual analyst and investor event will be webcast live and may be accessed through Relay Therapeutics website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations .

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Thursday, June 16, 2022
Security (finance), GIST, Nicollet Mall, HER2/neu, COVID-19, Madison Avenue, Annual report, FGFR2, Prospectus, Attention, U.S. Securities and Exchange Commission, LLC, Forward-looking statement, Private Securities Litigation Reform Act, Guggenheim Partners, B cell, Cogent, Sale, Jefferies Group, SEC, Nasdaq, Mutation, Patient, SEC filing, Telephone, KIT, CO, Form, GLOBE

The shares of common stock sold include 2,730,000 shares pursuant to the option to purchase additional shares granted by Cogent to the underwriters, which option was exercised in full.

Key Points: 
  • The shares of common stock sold include 2,730,000 shares pursuant to the option to purchase additional shares granted by Cogent to the underwriters, which option was exercised in full.
  • The public offering price of each share of common stock was$8.25and the public offering price of each pre-funded warrant was$8.24.
  • The aggregate gross proceeds to Cogent from this offering were approximately$172.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

Retrieved on: 
Tuesday, June 14, 2022
Madison Avenue, Nicollet Mall, LLC, Form, Annual report, Forward-looking statement, SEC filing, Security (finance), HER2/neu, Telephone, U.S. Securities and Exchange Commission, KIT, Guggenheim Partners, Nasdaq, FGFR2, Sale, GLOBE, Patient, Private Securities Litigation Reform Act, COVID-19, Prospectus, SEC, Jefferies Group, Attention, B cell, GIST, CO, Mutation, Cogent

and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,698 shares of its common stock, offered at a public offering price of $8.25 per share.

Key Points: 
  • and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,698 shares of its common stock, offered at a public offering price of $8.25 per share.
  • In addition, in lieu of issuing common stock to certain investors, Cogent is offering pre-funded warrants to purchase 3,030,302 shares of its common stock at a purchase price of$8.24per pre-funded warrant, which equals the public offering price per share of the common stock less the$0.01exercise price per share of each pre-funded warrant.
  • In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 2,730,000 shares of its common stock at the public offering price less underwriting discounts.
  • All of the shares of common stock and pre-funded warrants in the offering are being sold by Cogent.

Cogent Biosciences Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, June 13, 2022
Madison Avenue, Nicollet Mall, LLC, Form, Annual report, Forward-looking statement, Security (finance), HER2/neu, Telephone, U.S. Securities and Exchange Commission, KIT, Guggenheim Partners, Nasdaq, FGFR2, Sale, GLOBE, Patient, Private Securities Litigation Reform Act, Prospectus, Cogent, COVID-19, SEC, Jefferies Group, Attention, B cell, GIST, CO, Mutation

and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.

Key Points: 
  • and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.
  • In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock.
  • All of the shares in the offering are being offered by Cogent.
  • Jefferies, Piper Sandler & Co. and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Retrieved on: 
Friday, June 10, 2022
ASM, Congress, Part Two, Intracranial hemorrhage, Anemia, The Twilight Saga: Breaking Dawn – Part 1, LinkedIn, Annual report, Forward-looking statement, Mastocytosis, Webcast, HER2/neu, Disease, KIT, AML, Nasdaq, Dana–Farber Cancer Institute, FGFR2, Physician, CMML, Risk, Neutropenia, PEAK, Patient, MCL, GLOBE, Division, Acute myeloid leukemia, BID, Private Securities Litigation Reform Act, Mast cell leukemia, Chronic myelomonocytic leukemia, EHA, Peripheral edema, SEC, Twitter, Social media, Clinical trial, B cell, GIST, Thrombocytopenia, APEX, CNS, Mutation, Safety, Pharmaceutical industry, Risk management, Leukemia, Cogent

CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The data are being presented today in a poster presentation at the 2022 European Hematology Association (EHA) Congress in Vienna, Austria.

Key Points: 
  • and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).
  • APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
  • Patients were enrolled with the following sub-types: two patients with aggressive systemic mastocytosis (ASM), eight patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and one patient with mast cell leukemia (MCL).
  • As of the data cutoff date ofMay 24, 2022, all 11 patients treated were evaluated for signs of clinical activity.

Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET

Retrieved on: 
Monday, June 6, 2022
LinkedIn, Webcast, HER2/neu, KIT, FGFR2, Patient, Social media, Twitter, B cell, GIST, Mutation, Broadcasting, Pharmaceutical industry

The webcast will be accessible through the Investors and Media section of Cogents website at www.cogentbio.com .

Key Points: 
  • The webcast will be accessible through the Investors and Media section of Cogents website at www.cogentbio.com .
  • Following the live webcast, an archived replay will also be available.
  • Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.
  • Cogent Biosciences is based inCambridge, MAandBoulder, CO.Visit our website for more information at www.cogentbio.com .Follow Cogent Biosciences on social media: Twitter and LinkedIn .